Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F P Vleggaar

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal of Hepatology|November 4, 2000
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitisH R van Buuren, van Hoogstraten HJE, T Terkivatan, et al.
Scandinavian Journal of Gastroenterology. Supplement|March 10, 2001
Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disordersF P Vleggaar, N A Van Ooteghem, H R Van Buuren, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 13, 2011
Endoclips for fixation of nasoenteral feeding tubes: a reviewA M Schrijver, P D Siersema, F P Vleggaar, et al.
European Journal of Gastroenterology & Hepatology|July 27, 1999
Prevention and treatment of osteoporosis in primary biliary cirrhosisF P Vleggaar, H R van Buuren, F H Wolfhagen, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 1, 2008
[British and American screening guidelines inadequate for prevention of colorectal carcinoma in patients with inflammatory bowel disease]F P Vleggaar, M W M D Lutgens, B Oldenburg, et al.
Gut|July 17, 2001
Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variantF P Vleggaar, H R van Buuren, P E Zondervan, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1996
Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic modelJ G den Hollander, J W Mouton, M P van Goor, et al.
Lancet (London, England)|July 16, 1999
Sclerosing pancreato-cholangitis responsive to steroid therapyG W Erkelens, F P Vleggaar, W Lesterhuis, et al.
Endoscopy|December 18, 2010
Esophageal perforation due to removal of partially covered self-expanding metal stents placed for a benign perforation or leakM M C Hirdes, F P Vleggaar, K Van der Linde, et al.
European Journal of Gastroenterology & Hepatology|March 15, 2001
No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over studyF P Vleggaar, H R van Buuren, G P van Berge Henegouwen, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of Hepatology|November 4, 2000
High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitisH R van Buuren, van Hoogstraten HJE, T Terkivatan, et al.
Scandinavian Journal of Gastroenterology. Supplement|March 10, 2001
Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disordersF P Vleggaar, N A Van Ooteghem, H R Van Buuren, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 13, 2011
Endoclips for fixation of nasoenteral feeding tubes: a reviewA M Schrijver, P D Siersema, F P Vleggaar, et al.
European Journal of Gastroenterology & Hepatology|July 27, 1999
Prevention and treatment of osteoporosis in primary biliary cirrhosisF P Vleggaar, H R van Buuren, F H Wolfhagen, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 1, 2008
[British and American screening guidelines inadequate for prevention of colorectal carcinoma in patients with inflammatory bowel disease]F P Vleggaar, M W M D Lutgens, B Oldenburg, et al.
Gut|July 17, 2001
Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variantF P Vleggaar, H R van Buuren, P E Zondervan, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1996
Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic modelJ G den Hollander, J W Mouton, M P van Goor, et al.
Lancet (London, England)|July 16, 1999
Sclerosing pancreato-cholangitis responsive to steroid therapyG W Erkelens, F P Vleggaar, W Lesterhuis, et al.
Endoscopy|December 18, 2010
Esophageal perforation due to removal of partially covered self-expanding metal stents placed for a benign perforation or leakM M C Hirdes, F P Vleggaar, K Van der Linde, et al.
European Journal of Gastroenterology & Hepatology|March 15, 2001
No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over studyF P Vleggaar, H R van Buuren, G P van Berge Henegouwen, et al.
Pageof 4